-

scPharmaceuticals Announces New Presentation Time for BMO’s Virtual 2020 Prescriptions for Success Healthcare Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a new presentation time for BMO’s Virtual 2020 Prescriptions for Success Healthcare Conference, which is being held on Tuesday, June 23. John Tucker, chief executive officer, is now scheduled to present at 2:30pm EDT. The original announced presentation time was 11:30am EDT.

A live webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com, and will be archived for ninety days.

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Contacts

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com

scPharmaceuticals Inc.

NASDAQ:SCPH

Release Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) today announced a new presentation time for BMO’s Virtual 2020 Prescriptions for Success Healthcare Conference.
Release Versions

Contacts

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com

More News From scPharmaceuticals Inc.

scPharmaceuticals Provides Business Update

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals provided a business update on FUROSCIX®, its investigational proprietary formulation of furosemide for subcutaneous administration,...

scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX® (furosemide) for subcutaneous administration

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals to host a KOL call on an investigational drug for the outpatient treatment of congestion in patients with heart failure....

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals announced it will present at the virtual HC Wainwright Annual Global Investment and Cantor Fitzgerald Global Healthcare Conferences...
Back to Newsroom